Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Health

"Cancer Vaccine Partnering Terms and Agreements" now available at Fast Market Research


Print article Print article
2013-12-23 16:16:29 - New Pharmaceuticals market report from Current Partnering: "Cancer Vaccine Partnering Terms and Agreements"

The Cancer Vaccine Partnering Agreements report provides an understanding and access tthe cancer vaccine partnering deals and agreements entered intby the worlds leading healthcare companies.

Trends in cancer vaccine partnering deals
Disclosed headlines, upfronts, milestones and royalties by stage of development
Cancer vaccine partnering contract documents
Top cancer vaccine deals by value

The Cancer Vaccine Partnering Agreements report provides an understanding and access tthe cancer vaccine partnering deals and agreements entered intby the worlds leading healthcare companies.

Full Report Details at
- www.fastmr.com/prod/756326_cancer_vaccine_partnering_terms_and_a ..

The report provides an understanding and analysis of how and why companies enter cancer vaccine partnering deals. The majority of deals are discovery or development stage whereby the

licensee obtains a right or an option right tlicense the licensors vaccine technology. These deals tend tbe multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report alsincludes adjuvant deals and alliances.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight intthe negotiation process in terms of what you can expect tachieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases dnot.

This report contains over 200 links tonline copies of actual cancer vaccine deals and where available, contract documents as submitted tthe Securities Exchange Commission by companies and their partners. Contract documents provide the answers tnumerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability tderive value from the deal.

The initial chapters of this report provide an orientation of cancer vaccine dealmaking and business activities. Chapter 1 provides an introduction tthe report, whilst chapter 2 provides an overview of the trends in cancer vaccine dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.It alsprovides the number of deals entered by top 50 big pharma, big biotech and most active dealmakers in cabcer vaccine partnering.

Chapter 3 provides a review of the leading cancer vaccine deals since 2007. Deals are listed by headline value, signed by big pharma and big biotech. Where the deal has an agreement contract published at the SEC a link provides online access tthe contract.

Chapter 4 provides a comprehensive and detailed review of cancer vaccine partnering deals signed and announced since January 2007, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink tan online version of the deal record and where available, the contract document, providing easy access teach contract document on demand.

The report alsincludes numerous tables and figures that illustrate the trends and activities in cancer vaccine partnering and dealmaking since 2007. This report comes with an additional appendix containing entire list of cancer vaccine dealmakers by Company A-Z, deal type and stage of development.

In conclusion, this report provides everything a prospective dealmaker needs tknow about partnering in the research, development and commercialization of cancer vaccine technologies and products.

Report scope

Cancer Vaccine Partnering Agreements is intended tprovide the reader with an in-depth understanding and access tcancer vaccine trends and structure of deals entered intby leading companies worldwide.

Cancer Vaccine Partnering Agreements includes:

* Trends in cancer vaccine dealmaking in the biopharma industry since 2007
* Analysis of cancer vaccine deal structure
* Access theadline, upfront, milestone and royalty data
* Access tover 200 cancer vaccine deal records
* The leading cancer vaccine deals by value since 2007
* Includes adjuvant and drug delivery deals and alliances since 2007

In Cancer Vaccine Partnering Agreements, the available deals are listed by:

* Company A-Z
* Headline value
* Stage of development at signing
* Deal component type
* Specific oncology therapy target

Each deal title links via Weblink tan online version of the deal record and where available, the contract document, providing easy access teach contract document on demand.

The Cancer Vaccine Partnering Agreements report provides comprehensive access tavailable deals and contract documents for over 500 cancer vaccine deals. Analyzing actual contract agreements allows assessment of the following:

* What are the precise rights granted or optioned?
* What is actually granted by the agreement tthe partner company?
* What exclusivity is granted?
* What is the payment structure for the deal?
* How aresales and payments audited?
* What is the deal term?
* How are the key terms of the agreement defined?
* How are IPRs handled and owned?
* Whis responsible for commercialization?
* Whis responsible for development, supply, and manufacture?
* How is confidentiality and publication managed?
* How are disputes tbe resolved?
* Under what conditions can the deal be terminated?

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.


Author:
Bill Thompson
e-mail
Web: www.fastmr.com
Phone: 18008448156

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com | BidVertiser